The covid-19 vaccine from BioNTech/Pfizer is not nearly as effective when it comes to the new Delta variant as it is on previous versions of the virus.
This is according to preliminary studies done by the Israeli Ministry of Health, according to the Financial Times.
The studies show that BioNTech/Pfizer's vaccine is 64 percent effective in preventing fully vaccinated people from being infected with the Delta variant. This is lower than for other strains of the virus, where the vaccine is 94 percent effective.
The same studies also show that the vaccine is 93 percent effective in preventing serious illness and hospitalization.
AGC Biologics contacted minister over Danish vaccine collaboration before PM announcement
Sanofi to establish mRNA vaccine center with 400 employees
Pfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in Denmark
More from MedWatch
Rumored GN purchase unlikely but not impossible, say analysts
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
Bavarian Nordic eyes European monkeypox approval for smallpox vaccine
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.
New CFO wants to shake things up at WSA
A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.
Chinese patent expiration dates draw closer for Novo Nordisk
In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
EMA begins analyzing Bavarian Nordic's vaccine against monkeypox
Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Senior QA Specialist 
Cell Culture Scientist/Senior Scientist 
Clinical Project Manager 
Project Manager & Scrum Master 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Innovation Project Manager, Display Unit 
Director for innovative pre-clinical testing unit 
Clinical Trial Manager for development of in vitro diagnostics 
Senior Chemical Safety Advisor 
Account Manager 
Senior Project Manager (GMP - Life Science) 
Production Director 
Client Talent Acquisition Specialist 
SAP System Specialist (Product Supply) – Business Application Services 
Nordic Medical Affairs Manager